MedtronicMDTEarnings & Financial Report
Medtronic plc is an Irish medical device company. The company's legal and executive headquarters are in Ireland, while its operational headquarters are in Minneapolis, Minnesota. Medtronic rebased to Ireland following its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.
MDT Q2 2026 Key Financial Metrics
Revenue
$9.0B
Gross Profit
$5.9B
Operating Profit
$1.7B
Net Profit
$1.4B
Gross Margin
65.8%
Operating Margin
18.8%
Net Margin
15.3%
YoY Growth
6.6%
EPS
$1.07
Financial Flow
Medtronic Q2 2026 Financial Summary
Medtronic reported revenue of $9.0B for Q2 2026, with a net profit of $1.4B (15.3% margin). Cost of goods sold was $3.1B, operating expenses totaled $4.2B.
Key Financial Metrics
| Total Revenue | $9.0B |
|---|---|
| Net Profit | $1.4B |
| Gross Margin | 65.8% |
| Operating Margin | 18.8% |
| Report Period | Q2 2026 |
Medtronic Annual Revenue by Year
Medtronic annual revenue history includes year-by-year totals (for example, 2025 revenue was $33.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $33.5B |
| 2024 | $32.4B |
| 2023 | $31.2B |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.09B | $8.59B | $7.92B | $8.40B | $8.29B | $8.93B | $8.58B | $8.96B |
| YoY Growth | 4.7% | 0.5% | 2.8% | 5.2% | 2.5% | 3.9% | 8.4% | 6.6% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $90.84B | $89.98B | $89.75B | $90.04B | $89.97B | $91.68B | $90.97B | $91.35B |
| Liabilities | $38.84B | $39.56B | $41.59B | $41.33B | $40.36B | $43.42B | $42.84B | $42.49B |
| Equity | $51.79B | $50.21B | $47.95B | $48.49B | $49.39B | $48.02B | $47.89B | $48.65B |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.47B | $2.78B | $986.0M | $958.0M | $2.57B | $2.53B | $1.09B | $925.0M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M
DXCM
Dexcom
Revenue
$1.3B
Net Profit
$267.3M
EW
Edwards Lifesciences
Revenue
$1.6B
Net Profit
$291.1M
GEHC
GE HealthCare
Revenue
$5.7B
Net Profit
$588.0M
HOLX
Hologic
Revenue
$1.0B
Net Profit
$179.1M
IDXX
Idexx Laboratories
Revenue
$1.1B
Net Profit
$274.6M
PODD
Insulet Corporation
Revenue
$783.7M
Net Profit
$101.6M